ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.

Maria Gebre-MedhinEva BrunPer EngströmHedda Haugen CangeLalle Hammarstedt-NordenvallJohan ReizensteinJan Nyman Edvard AbelSigne FrieslandHelena SjödinHenrik CarlssonKarin SöderkvistMarcus ThomassonBjörn Zackrisson Per Nilsson

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

Cetuximab is inferior to cisplatin regarding locoregional control for concomitant treatment with RT in patients with locoregionally advanced HNSCC. Additional studies are needed to identify possible subgroups that still may benefit from concomitant cetuximab treatment.

Keyphrases

squamous cell
phase iii
locally advanced
clinical trial
metastatic colorectal cancer
open label
rectal cancer
wild type
radiation therapy
replacement therapy
smoking cessation
double blind
lymph node metastasis
childhood cancer